Device Trial Radar · NCT04293861
Evaluation of the Evolution of Biological and Imaging Markers of Bone and Cartilage Degradation in Patients With Knee Osteoarthritis Receiving Intra-articular Injections of a Hyaluronan Derivative HYMOVIS®
Last checked: Nov 20, 2026Latest source record: Mar 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Apr 1, 2015
Primary completion
Jun 6, 2017
Study completion Jun 6, 2017
Sponsor
- Lead sponsor
- Fidia Farmaceutici s.p.a.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 3, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study MOKHA is aimed to evaluate the beneficial effect of HYMOVIS® on cartilage of patients suffering of knee osteoarthritis as revealed by using scientifically sound, objective measurements of biological and MRI-based imaging markers.
Conditions
- Knee Osteoarthritis
Interventions
HYMOVISDevice
HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the variation of type II collagen-specific biomarkers (Coll2-1, Coll2-1NO2 & CTX-II) after HYMOVIS® treatment versus baselineTime frame: Variation of levels of biomarkers from baseline (V1) trough 1 year follow up (V8)
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Service de Rhumatologie, CHU Brugmann
Brussels, Belgium
CHR Citadelle de Liège
Liège, Belgium
Service de Rhumatologie CHU Liège
Liège, Belgium
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.